|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All Patients****N=59** | **Part I Total****N=29** | **Part II Total****N=30** | **Part II Cohort A****N=28** |
| Afuresertib daily dose, mg | 117.30 (41.5‒142.0) | 106.00 (41.5‒136.9) | 125.00 (60.0‒142.0) | 124.85 (60.0‒142.0) |
| Time on afuresertib treatment, months | 6.10(0.2‒13.2) | 5.70(0.2‒10.4) | 6.55(0.2‒13.2) | 6.55(0.2‒13.2) |
| Dose intensity of paclitaxel, mg/week | 89.30 (42.2‒123.3) | 88.80(42.2‒110.8) | 89.95 (62.0‒123.3) | 89.95(62.0‒123.3) |
| Dose intensity of carboplatin, mg/week | 150.40 (63.1‒231.8) | 144.00 (63.1‒200.0) | 152.95 (76.9‒231.8) | 152.95 (76.9‒231.8) |
| Cycles of paclitaxel, n | 6.0(1‒6) | 5.0(1‒6) | 6.0(1‒6) | 6.0(1‒6) |
| Cycles of carboplatin, n | 6.0(1‒6) | 6.0(1‒6) | 6.0(1‒6) | 6.0(1‒6) |

**Supplemental Table S1.** Summary of exposure to afuresertib, paclitaxel and carboplatin (ITT population).

All data are presented as median (range) values.